Literature DB >> 9811160

Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.

L L von Moltke1, D J Greenblatt, J M Grassi, B W Granda, K Venkatakrishnan, J Schmider, J S Harmatz, R I Shader.   

Abstract

Cytochromes mediating the biotransformation of dextromethorphan to dextrorphan and 3-methoxymorphinan, its principal metabolites in man, have been studied by use of liver microsomes and microsomes containing individual cytochromes expressed by cDNA-transfected human lymphoblastoid cells. In-vitro formation of dextrorphan from dextromethorphan by liver microsomes was mediated principally by a high-affinity enzyme (Km (substrate concentration producing maximum reaction velocity) 3-13 microM). Formation of dextrorphan from 25 microM dextromethorphan was strongly inhibited by quinidine (IC50 (concentration resulting in 50% inhibition) = 0.37 microM); inhibition by sulphaphenazole was approximately 18% and omeprazole and ketoconazole had minimal effect. Dextrorphan was formed from dextromethorphan by microsomes from cDNA-transfected lymphoblastoid cells expressing CYP2C9, -2C19, and -2D6 but not by those expressing CYP1A2, -2E1 or -3A4. Despite the low in-vivo abundance of CYP2D6, this cytochrome was identified as the dominant enzyme mediating dextrorphan formation at substrate concentrations below 10 microM. Formation of 3-methoxy-morphinan from dextromethorphan in liver microsomes proceeded with a mean Km of 259 microM. For formation of 3-methoxymorphinan from 25 microM dextromethorphan the IC50 for ketoconazole was 1.15 microM; sulphaphenazole, omeprazole and quinidine had little effect. 3-Methoxymorphinan was formed by microsomes from cDNA-transfected lymphoblastoid cells expressing CYP2C9, -2C19, -2D6, and -3A4, but not by those expressing CYP1A2 or -2E1. CYP2C19 had the highest affinity (Km = 49 microM) whereas CYP3A4 had the lowest (Km = 1155 microM). Relative abundances of the four cytochromes were determined in liver microsomes by use of the relative activity factor approach. After adjustment for relative abundance, CYP3A4 was identified as the dominant enzyme mediating 3-methoxymorphinan formation from dextromethorphan, although CYP2C9 and -2C19 were estimated to contribute to 3-methoxymorphinan formation, particularly at low substrate concentrations. Although formation of dextrorphan from dextromethorphan appears to be sufficiently specific to be used as an in-vitro or in-vivo index reaction for profiling of CYP2D6 activity, the findings raise questions about the specificity of 3-methoxymorphinan formation as an index of CYP3A activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811160     DOI: 10.1111/j.2042-7158.1998.tb06914.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  14 in total

1.  A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology.

Authors:  Matthew G Soars; Harry V Gelboin; Kristopher W Krausz; Robert J Riley
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

2.  Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.

Authors:  Michael A Mohutsky; Jenny Y Chien; Barbara J Ring; Steven A Wrighton
Journal:  Pharm Res       Date:  2006-03-24       Impact factor: 4.200

Review 3.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

4.  Pharmacokinetic profile of dextromethorphan hydrobromide in a syrup formulation in children and adolescents.

Authors:  Eric Guenin; Marianna Armogida; Dennis Riff
Journal:  Clin Drug Investig       Date:  2014-09       Impact factor: 2.859

5.  Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.

Authors:  Z Desta; N V Soukhova; D A Flockhart
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 6.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Influence of hydroxychloroquine on the bioavailability of oral metoprolol.

Authors:  M Somer; J Kallio; U Pesonen; K Pyykkö; R Huupponen; M Scheinin
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

8.  The antitussive effect of dextromethorphan in relation to CYP2D6 activity.

Authors:  R Abdul Manap; C E Wright; A Gregory; A Rostami-Hodjegan; S T Meller; G R Kelm; M S Lennard; G T Tucker; A H Morice
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

9.  Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells.

Authors:  S Choi; B Sainz; P Corcoran; S Uprichard; H Jeong
Journal:  Xenobiotica       Date:  2009-03       Impact factor: 1.908

10.  Does compound I vary significantly between isoforms of cytochrome P450?

Authors:  Richard Lonsdale; Julianna Oláh; Adrian J Mulholland; Jeremy N Harvey
Journal:  J Am Chem Soc       Date:  2011-09-12       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.